Where does Neurocrine Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Neurocrine Biosciences, Inc. ranks #6,681 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Neurocrine Biosciences, Inc. hold?

Neurocrine Biosciences, Inc. holds 50 US utility patents granted between 2015 and 2025, spanning 6 technology areas.

What is Neurocrine Biosciences, Inc.'s Innovation Score?

Neurocrine Biosciences, Inc. has an Innovation Score of 37.3 out of 100 (top 44% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Neurocrine Biosciences, Inc. focus on?

Neurocrine Biosciences, Inc.'s top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 42 patents, ranking #431 of 6,058 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Neurocrine Biosciences, Inc.'s patent grant rate increasing or decreasing?

Neurocrine Biosciences, Inc.'s recent grant velocity is +162% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Neurocrine Biosciences, Inc.'s patents?

Neurocrine Biosciences, Inc.'s patents average 20.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Neurocrine Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Neurocrine Biosciences, Inc.

USPTO PatentsView assignee record - 50 granted patents across 6 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Neurocrine ranks #6,681 of 49,997 tracked US assignees by granted-patent volume, with 50 patents across 6 technology areas.

#6,681
of 49,997 US assignees by volume: Top 44%
by Innovation Score (37.3/100): 20.1
avg claims per patent: +162%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6681 · US Corporation #6,681 · 50 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 50 grants
UPPER-Q #6,681/49,997
PHOTO-FINISH Navajo Manufacturing
CPC-NARROW A61P · 6 areas
INNOV-THIN 37.3/100
CLAIMS-DENSE 20.1 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +162% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Navajo Manufacturing Company, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Neurocrine’s 37.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.6 pts (36%) Velocity 2.9 pts (8%) Breadth 8.7 pts (23%) Claim depth 12.1 pts (32%)

Qualcomm Incorporated · highest

85
Canon Information… · near

37
Crinetics Pharmaceut… · near

37
Legacy Ventures · near

37
Neurocrine Biosciences · this assignee

37
Nippon Micrometal · near

37
3D Lighting… · lowest

7

What this shows Neurocrine's Innovation Score is 37.3/100 (top 44% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Neurocrine?

Each dot is one of Neurocrine’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Neurocrine’s own 20.1 claims/patent is ABOVE the 11.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Neurocrine vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Neurocrine's grants concentrate

Neurocrine Biosciences, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 84% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2021 (16 grants) versus a trough of 1 in 2015. By volume, Neurocrine sits between Ningbo Institute OF Materials Technology & Engineering, Chinese Academy OF Sciences and Omax Corporation.

Neurocrine's three-year grant acceleration

From 2019–2021 to 2022–2024, Neurocrine Biosciences, Inc. moved from 25 to 11 grants (0.44x the prior three-year total, a multiple, not a CAGR). See the growth leaderboard.

Ningbo Institute…

50
Nippon Shinyaku

50
NUC

50
Navajo Manufactur…

50
Nguyen Gaming

50
Northrop Grumman…

50
Ocean's King Ligh…

50
Omax

50
Neurocrine Biosci… ◀

50

What this shows Neurocrine holds 50 patents at rank #6,683, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Neurocrine

By rank, the assignees closest to #6,683 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Neurocrine's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Neurocrine, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Neurocrine ranks #431 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (37 here).

Canon Information and Imaging Solutions, Inc. 37 Legacy Ventures LLC 37 Crinetics Pharmaceuticals, Inc. 37 Nippon Micrometal Corporation 37

Similar claim depth

Nearest assignees by average claims per patent (20.1 here).

Evertz Microsystems Ltd. 20.1 avg Kateeva, Inc. 20.1 avg Brain Corporation 20.1 avg Royal Bank of Canada 20.1 avg

Neurocrine's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

37 Top 44% higher than 56% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Neurocrine Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	2.0%
2016	2	4.0%
2017	3	6.0%
2018	5	10.0%
2019	2	4.0%
2020	7	14.0%
2021	16	32.0%
2022	4	8.0%
2023	4	8.0%
2024	3	6.0%
2025partial year	3	6.0%

Which technologies does Neurocrine Biosciences, Inc. patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

C07D - Heterocyclic Compounds 39

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 6

C07C - Acyclic OR Carbocyclic Compounds 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 1

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Neurocrine Biosciences, Inc.'s patent record in context - here's where to go next.

Neurocrine Biosciences, Inc.'s lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 84% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,681 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Neurocrine Biosciences, Inc. against Ningbo Institute OF Materials Technology & Engineering, Chinese Academy OF Sciences, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 37.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.